Format

Send to

Choose Destination
See comment in PubMed Commons below
Zhongguo Dang Dai Er Ke Za Zhi. 2014 Jun;16(6):584-8.

[Management of anti-N-methyl-D-aspartate receptor encephalitis in children].

[Article in Chinese]

Author information

1
Department of Pediatric Neurology, Jiangxi Children's Hospital, Nanchang 330006, China. zhongjm@163.com.

Abstract

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a new category of severe, potentially treatable autoimmune encephalitis and can appear in patients of all ages, but more frequently in children. It is a highly characteristic syndrome evolving in five stages: the prodromal phase (viral infection-like symptoms), psychotic phase, unresponsive phase, hyperkinetic phase, and gradual recovery phase. The treatment for this disorder includes first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumor removal. Hereby the progresses, selections and shortcomings of the treatment protocols for this disease are introduced.

PMID:
24927432
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Chinese Journal of Contemporary Pediatrics
    Loading ...
    Support Center